Clinical Trial Update: Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating dinaciclib in combination with bortezomib and dexamethasone in relapsed plasma cell myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Dinaciclib (dinaciclib)
• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Plasma Cell Myeloma | Phase 1 | Status: COMPLETED